期刊文献+

XRCC1基因多态性与胃癌新辅助化疗敏感相关性的研究 被引量:1

Correlated research of XRCC1 gene polymorphism and neoadjuvant chemotherapy sensitivity to advanced gastric cancer
原文传递
导出
摘要 目的:探讨XRCC1基因多态性与中晚期胃癌新辅助化疗敏感相关性。方法:将77例中晚期胃癌患者随机分为新辅助化疗组(36例)和常规手术对照组(41例),所有患者均行手术治疗,并经术后病理确诊。采用荧光直接测序法测定XRCC1 399位点多态性与中晚期胃癌新辅助化疗疗效的关系。结果:新辅助化疗组肿瘤细胞坏死率(35.60%)明显高于对照组(3.52%)。新辅助化疗组A/A(55.82%)肿瘤细胞坏死率明显高于A/G(32.13%)及G/G(9.17%)的肿瘤细胞坏死率。新辅助化疗组的组织学有效率为41.70%。通过观察化疗前后的CT图片并结合术中探查,新辅助化疗组患者CR 2例(5.60%),PR 15例(41.60%),SD 14例(38.90%),PD 5例(13.90%),总反应率为47.20%。新辅助化疗组根治性手术切除率(80.56%)明显高于对照组(58.54%),P=0.037。结论:中晚期胃癌新辅助化疗组XRCC1基因399位点A/A多态性与肿瘤细胞坏死率存在相关性,可以作为中晚期胃癌新辅助化疗敏感性的基因水平预测指标。 OBJECTIVE:To detect the correlation of XRCC1 gene polymorphism and neoadjuvant chemotherapy sen- sitivity to advanced gastric cancer. METHODS:Totally 77 advanced gastric cancer patients were selected and randomly di- vided into neoadjuvant chemotherapy group (n= 36) and routine procedure control group (n= 41). All the patients re- ceived surgery and diagnosed by post-operative pathology. XRCC1 399 loci polymorphic were detected by fluorescence based direct sequencing neoadjuvant chemotherapy effect. RESULTS: The tumor cell necrosis rate(35.60%) in neoadju- vant chemotherapy group was obviously higher than that in control group(3.52 %). In neoadjuvant chemotherapy group, A/A group (55.82%) tumor cell necrosis rate was obviously higher than that in A/G(32. 13%) and G/G(9. 17%) group. The histological effective rate was 41.70%. Through CT demonstration before and after chemotherapy,combined with surgical exploration,there were CR in 2 patients(5.60%) ,PR in 15 patients(41.60%) ,SD in 14 patients(38.90%), PD in 5 patients(13.90 %) and total response rate was 47.20 %. The resection rate(80.56 % ) in neoadjuvant chemothera- py group was obviously higher than that in control group(58.54% ,P=0. 037). CONCLUSIONS: XRCC1399A/A SNP is related with tumor cell necrosis rate in neoadjuvant chemotherapy group. XRCC1 399A/A SNP can be a genetic predict index to neoadjuvant chemotherapy sensitivity in advanced gastric cancer.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第19期1477-1479,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 胃肿瘤/药物疗法 基因 XRCC1多态现象 药物疗法 联合 stomach neoplasms/drug therapy genes,XRCC1 polymorphism drug therapy,combination
  • 相关文献

参考文献6

二级参考文献39

  • 1楚建设,吴清艺.顺铂腹腔内滴灌联合全身化疗治疗晚期胃癌临床观察[J].中华肿瘤防治杂志,2007,14(10):786-787. 被引量:10
  • 2赵蕊,杨华,顾玮瑾,蔡宏.我国恶性肿瘤手术中无瘤操作技术的进展[J].中华护理杂志,2007,42(8):730-732. 被引量:60
  • 3Cuschieri A, Fayers P, Fielding J, et al. PostoPerative morbid- ity and mortality after DlandD2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative GrouP[J]. Lancet, 1996,347 (0007) :995 - 999. 被引量:1
  • 4Bonenkamp J J, Hermans J, Sasako M, et al. Extended lymph node dissection for gastric cancer[J]. N Enel J Med, 1999,340 (12) :905- 914. 被引量:1
  • 5Wanebo N, Kennedy BJ, Chmiel J, et al. Cancer of the stomach [J]. Ann Surg,1993,218(5) :583- 592. 被引量:1
  • 6Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric carcinoma[J]. Cancer,2000,89(7) : 1418 - 1424. 被引量:1
  • 7Maruyama K, Okaboyashi K, Kinoshita T. Progress in gastric cancer surgery and its limits of radieality[J]. World J Surg, 1987,11:418- 425. 被引量:1
  • 8Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin,2005,55(2) :74-108. 被引量:1
  • 9Wagner A D, Unverzagt S, Grothe W,et al. Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev, 2010,3 (1) : 40-64. 被引量:1
  • 10Shah M A, Schwartz G K. Treatment of metastatic esophagus and gastric cancer[J]. Seminars Oncol, 2004,31(4):574-587. 被引量:1

共引文献28

同被引文献16

  • 1Nakagawa S, Nashimoto A, Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in treatment of loca|ly advanced gas- tric cancer[ J]. Gastric Cancer,2007,10( 1 ) :29 - 34. 被引量:1
  • 2Marsh S, Mcleod HL. Cancer pharmacogenetics[ J ]. Br J Cancer, 2004,90(1) :8 -11. 被引量:1
  • 3Matrai Z, Peley G, Kovacs T, et al. Cytore-ductive surgery and intra- peritoneal hyperthermic chemoperfusion for peritoneal carcinomatosis caused by recurrent inflammatory myofibroblastic sarcoma: a case re- port and review of the literature [ J ]. Orv Hetil,2006,147 (g) : 147 - 158. 被引量:1
  • 4Shimoyama S. Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment[ J]. J Gastroenterol Hepatol, 2009,24 ( 6 ) : 970 - 981. 被引量:1
  • 5Fikrova P,Stetina R,Hrnciarik M,et al. Detection of DNA crosslinks in peripheral lymphoeytes isolated from patients treated with plati- num derivates using modified comet assay[ J]. Neoplasma,2013,60 (4) :413 -418. 被引量:1
  • 6Liu B,Wei J,Zou Z,et al. Polymorphistn of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemo- therapy in Chinese population [ J]. Eur J Hum Genet,2007, 15 (10) :1049 - 1053. 被引量:1
  • 7Huang ZH, Hua D, Du X. Polymorphisms in p53, GSTP and XRCC1predict relapse and survival of gastric cancer patients treated with ox- aliplatin-based adjuvant chemotherapy[J]. Cancer Chemother Phar- macol,2009,64( 5 ) : 1001 - 1007. 被引量:1
  • 8黄朝晖,华东,李莉华,吴小红,宋明旭,刘志辉,周希科,朱景德.XRCC 1 Arg399Gln基因多态性对铂类药物化疗胃癌患者预后的影响[J].肿瘤,2008,28(3):242-245. 被引量:5
  • 9梁军,吕红英,张克,梁华.ERCC1和XRCC1基因多态性与接受奥沙利铂化疗晚期大肠癌患者生存期的关系[J].中国肿瘤临床,2008,35(18):1068-1072. 被引量:12
  • 10邱东民,王丰.XRCC1基因多态性影响奥沙利铂对晚期胃癌患者化疗疗效敏感性的关系[J].放射免疫学杂志,2009,22(6):630-632. 被引量:2

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部